+44 (0)20 3910 4640 info@symmetron.net
  • 🗨 We’re hiring!
Symmetron
  • Services
  • Therapeutic areas
  • The Team
  • Careers
  • Contact
Select Page

Societal costs of Er+/Her2- advanced or metastatic breast cancer in post-menopausal women in the United Kingdom

by Symmetron | Jan 19, 2019

Cancer Societal costs of Er+/Her2- advanced or metastatic breast cancer in post-menopausal women in the United Kingdom Value in Health. 2017; 20(9):A427 Authors Bermingham S, Schmid P, Forster F, Cornic L, Theti D, Smith A Noteworthy This is the first study to...

The cost of somatisation among the working‐age population in England for the year 2008–2009

by Symmetron | Jan 17, 2019

Medically unexplained symptoms   The cost of somatisation among the working-age population in England for the year 2008–2009 Mental Health in Family Medicine. 2010;7:71–84 Awards Any awards or notable things to say about this?  Process \ A \ B \ C...

A cost-effectiveness analysis of nintedanib in idiopathic pulmonary fibrosis in the UK

by Symmetron | Jan 17, 2019

Idiopathic Pulmonary Fibrosis   A Cost-Effectiveness Analysis of Nintedanib in Idiopathic Pulmonary Fibrosis in the UK PharmacoEconomics. 2017 Apr;35(4):479-491 Authors Rinciog C, Watkins M, Chang S, Maher TM, LeReun C, Esser D, Diamantopoulos A  Process \ An...

The burden of illness of idiopathic pulmonary fibrosis: a comprehensive evidence review

by Symmetron | Jan 17, 2019

Idiopathic Pulmonary Fibrosis   The burden of illness of idiopathic pulmonary fibrosis:a comprehensive evidence review PharmacoEconomics. 2018;36:779–807 Awards Top PharmacoEconomics article of 2018! Downloads and counting Authors Diamantopoulos A, Wright E,...

Recent Comments

    Archives

    Categories

    Meta

    • Log in
    • Entries feed
    • Comments feed
    • WordPress.org
    • Privacy Policy
    © 2019 Symmetron Ltd